诺华制药(NVS.US)预计今年利润将出现下滑，原因是受心脏病药物诺欣妥等核心畅销药面临仿制药竞争的进一步冲击。该公司周三表示，按固定汇率计算，核心营业收入可能出现低个位数的降幅。销售额预计将增长低个位数。首席执行官Vas Narasimhan专注于创新药物的战略将在今年面临考验，因为诺欣妥及其他老牌畅销药正饱受仿制药竞争对手带来的压力。目前，诺诺华正在推出一款治疗自身免疫性皮肤病的新药，并将很快发布针对心脏病和多发性硬化症等实验性疗法的关键数据。诺华已承诺在美国建设七个新设施，这是其扩大在美制造布局的230亿美元投资计划的一部分。其中很大一部分将专注于放射配体疗法（RLT）——这是一种利用靶向药物将放射性同位素直接输送到肿瘤的癌症治疗方法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.